Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 186

Sort by

Sort Order Select

Journal Articles

Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-Fatigue): Cognitive Debriefing in Patients with Chronic Lymphocytic Leukemia (CLL)

Helena Chung, MA BA, Daniel Eek, PhD, Calvin Krogh, MBA MPH, Matthew Blowfield, MSc, Oren Meyers, PhD, Toby A. Eyre

Blood (2019) 134 (Supplement_1): 4777.

https://doi.org/10.1182/blood-2019-122849

Published: 2019

Journal Articles

Patient-Reported Outcomes (PRO) Data from Patients (Pts) with Essential Thrombocythemia (ET) Enrolled in the MOST Study

Ellen K. Ritchie, MD, Anas Al-Janadi, MD, Philomena Colucci, DO, MS, Patricia Kalafut, PhD, Dilan Paranagama, PhD, Ruben A. Mesa, MD

Blood (2019) 134 (Supplement_1): 1665.

https://doi.org/10.1182/blood-2019-124527

Published: 2019

Journal Articles

A Standardized Equation Model of Quality of Life in Myeloproliferative Neoplasms

Robyn M. Scherber, MDMPH, Martin M. Goros, MS, Jonathan Gelfond, MD PhD, Amylou C. Dueck, PhD, Sarah F Christensen, MD, Hans Hasselbalch, MD, Holly L. Geyer, MD, Ruben A Mesa, MD

Blood (2019) 134 (Supplement_1): 2181.

https://doi.org/10.1182/blood-2019-126803

Published: 2019

Journal Articles

Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib

Claire N Harrison, Professor, Nicolaas Schaap, MD PhD, Alessandro M Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Eric Jourdan, MD, Richard T. Silver, MD, Harry C Schouten, MD PhD, Francesco Passamonti, MD, Sonja Zweegman, Moshe Talpaz, MD, Srdan Verstovsek, MD PhD, Shelonitda Rose, Derek Tang, PhD BSPharm, Angela Hu, MS, EDM, Shien Guo, PhD, Weiqin Liao, MS, Carrie Brownstein, MD, Ruben A Mesa, MD

Blood (2019) 134 (Supplement_1): 2207.

https://doi.org/10.1182/blood-2019-129386

Published: 2019

Journal Articles

Ruxolitinib Shows Efficacy in Patients with Newly-Diagnosed Polycythemia Vera: Futility Analysis of the Randomized Ruxo-BEAT Clinical Trial of the German Study Group for Myeloproliferative Neoplasms

Steffen Koschmieder, Susanne Isfort, Dominik Wolf, Univ. Prof. Dr., Florian H. Heidel, Philippe Schafhausen, Martin Griesshammer, MD, Denise Wolleschak, Uwe Platzbecker, Konstanze Döhner, Philipp J. Jost, MD, Stefani B. Parmentier, Nikolas von Bubnoff, Frank Stegelmann, MD, Angela Maurer, Jeremy Franklin, Martina Crysandt, MD, Deniz Gezer, Martin Hellmich, Tim H Brümmendorf, MD

Blood (2019) 134 (Supplement_1): 2944.

https://doi.org/10.1182/blood-2019-123985

Published: 2019

Journal Articles

Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies

John N. Allan, MD, Krish Patel, MD, Anthony R. Mato, MDMSCE, William G. Wierda, MD PhD, Javier Pinilla Ibarz, MD PhD, Michael Y. Choi, MD, Susan M. O'Brien, MD, Jeff P. Sharman, MD, Mazyar Shadman, MD, Douglas E Gladstone, MD, Matthew S. Davids, MD, John M. Pagel, MD PhD DSc, Renee Ward, MD PhD, Gary Acton, MD, Pietro Taverna, PhD, Judith A. Fox, PhD, Richard R. Furman, MD, Jennifer R. Brown, MD PhD

Blood (2019) 134 (Supplement_1): 3041.

https://doi.org/10.1182/blood-2019-126286

Published: 2019

Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Myelofibrosis Treated with Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in the Randomized, Placebo-Controlled, Phase III JAKARTA Study

Ruben A Mesa, MD, Nicolaas Schaap, MD PhD, Alessandro M Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Francesco Passamonti, MD, Sonja Zweegman, Moshe Talpaz, MD, Srdan Verstovsek, MD PhD, Shelonitda Rose, Derek Tang, PhD BSPharm, Angela Hu, MS, EDM, Carrie Brownstein, MD, Shien Guo, PhD, Xiaomei Ye, MS, Claire N Harrison, Professor

Blood (2019) 134 (Supplement_1): 704.

https://doi.org/10.1182/blood-2019-129020

Published: 2019

Journal Articles

Patient-Centered Evaluation of Clinical Benefit in Acute Myeloid Leukemia: Importance of Early Engagement with Patients

Jill A. Bell, PhD MS, Farrah Anne Pompilus, MA, Alissa Rams, BA, Yanyan Zhu, PhD MPH, Anna Ciesluk, MPH, Rafael Bejar, MD PhD, Robert J. Fram, MD, Douglas V. Faller, MD PhD, Patrick Marquis, MD MBA

Blood (2019) 134 (Supplement_1): 5898.

https://doi.org/10.1182/blood-2019-128517

Published: 2019

Journal Articles

Symptom Assessment in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms at an Academic Medical Institution

Kelly L. Schoenbeck, MD, Miguel Carlos Cerejo, DO, Patricia A. Cornett, MD, Lloyd E. Damon, MD, Karin L. Gaensler, MD, Andrew D. Leavitt, MD, Aaron C. Logan, MD PhD, Gabriel N. Mannis, MD, Rebecca L. Olin, MD, Giselle Salmasi, MD, Peter H. Sayre, MD PhD, Neil P. Shah, MD PhD, Anand Dhruva, MD, Chloe E. Atreya, MD PhD, Catherine C. Smith, MD

Blood (2019) 134 (Supplement_1): 5859.

https://doi.org/10.1182/blood-2019-129638

Published: 2019

Journal Articles

Urine Proteomic Analysis Reveals Disease-Specific Patterns in Pediatric Patients with Classical Hodgkin's Disease(HD). an Addon Study to the Euronet-PHL-C2 Trial

Blood (2019) 134 (Supplement_1): 2804.

https://doi.org/10.1182/blood-2019-125611

Published: 2019

Journal Articles

Age Matters: Younger Unrelated PBSC Donors Experience Less G-CSF-Related Symptoms and Have a Faster Emotional Recovery Than Older Donors

Jose ROS Soto, MBBS, Eva Zoubek, PhD, Richard Szydlo, PhD, Paul Johnson, Ann O'Leary, Maria Del Mar Cuadrado, MBBS, Catherine Burlton, J. Alejandro Madrigal, MDPhDDSc,FRCP,FRCPath, Chloe Anthias, MD

Blood (2019) 134 (Supplement_1): 3249.

https://doi.org/10.1182/blood-2019-122304

Published: 2019

Journal Articles

Impact of Disease Burden in Myelofibrosis Patients: A Sub Analysis from Italian Romei Observational Study

Francesca Palandri, PhD MD, Massimo Breccia, MD, Carmine Selleri, MD, Francesco Mendicino, MD, Giuseppe A. Palumbo, MD PhD, Elisabetta Abruzzese, MD, Anna Marina Liberati, Nicola Di Renzo, MD, Fabrizio Pane, MD, Mario Tiribelli, Robin Foà, MD, Elena Maria Elli, MD, Giovanni Caocci, MD, Mara Morelli, MD, Paola Guglielmelli, MD PhD, Francesco Passamonti, MD

Blood (2019) 134 (Supplement_1): 4188.

https://doi.org/10.1182/blood-2019-125778

Published: 2019

Journal Articles

A Retrospective Real-World Study of the Current Treatment Pathways for Myelofibrosis in the UK (The REALISM UK Study)

Adam J. Mead, MD PhD, Tim Somervaille, Professor, MD, Nauman M Butt, MD, Waseem Nagi, MD FRCPath, Alastair J Whiteway, MBBS, Suriya Kirkpatrick, MD, Ciro R Rinaldi, MD PhD, Catherine Roughley, MD, Sam Ackroyd, MD, Joanne Ewing, PhDBMBS BSc FRPATH, Pratap Neelakantan, MD FRCPath, Mamta Garg, MD FRCP, FRCPath, Claire N Harrison, Professor, David Tucker, MD, Rozinder Bains, Gavin Chiu, MBBS, MRCGP, MFPM, DPM, BSc, Joe Hickey, PhD

Blood (2019) 134 (Supplement_1): 1671.

https://doi.org/10.1182/blood-2019-124686

Published: 2019

Journal Articles

Psychometric Evaluation of the Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-Fatigue) in Patients with Chronic Lymphocytic Leukemia (CLL)

Daniel Eek, PhD, Cristina Ivanescu, PhD, Leanne Kool-Houweling, MSc, David Cella, PhD

Blood (2019) 134 (Supplement_1): 4763.

https://doi.org/10.1182/blood-2019-123056

Published: 2019

Journal Articles

Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial

Blood (2018) 132 (Supplement 1): 3032.

https://doi.org/10.1182/blood-2018-99-111929

Published: 2018

Journal Articles

Preliminary Safety, Pharmacokinetic, and Pharmacodynamic Results from a Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton's Tyrosine Kinase Inhibitor (BTKi), Vecabrutinib, in B-Lymphoid Malignancies

John N. Allan, MD, William G. Wierda, MD PhD, Krish Patel, MD, Susan M. O'Brien, MD, Anthony R Mato, MD, Matthew S Davids, Richard R. Furman, MD, John M. Pagel, MD PhD, Judith A. Fox, PhD, Renee Ward, MD PhD, Pietro Taverna, PhD, Jennifer R. Brown, MD PhD

Blood (2018) 132 (Supplement 1): 3141.

https://doi.org/10.1182/blood-2018-99-116382

Published: 2018

Journal Articles

Personalized Therapy in Multicentric Castleman Disease Produces Excellent Outcomes in a Tertiary Referral Center

Katie Stone, BS, Francisco Socola, MD, Amy Greenway, Samina Waheed, Kristen Carter, APRN, Diane Glendinning, APRN, Daisy Alapat, MD, Frits van Rhee, MD PhD

Blood (2018) 132 (Supplement 1): 3701.

https://doi.org/10.1182/blood-2018-99-119510

Published: 2018

Journal Articles

Single-Cell RNA-Sequencing of Peripheral Blood Mononuclear Cells Reveals Changes in Immune Cell Composition and Distinct Inflammatory Gene Expression Profiles during Idiopathic Multicentric Castleman Disease Flare

Ruth-Anne Langan, BA, Dustin Shilling, PhD, Michael Gonzalez, PhD, Charlly Kao, PhD, Hakon Hakonarson, MD PhD, Taku Kambayashi, MD PhD, David C Fajgenbaum, MD MBA, MSc

Blood (2018) 132 (Supplement 1): 2406.

https://doi.org/10.1182/blood-2018-99-110461

Published: 2018

Journal Articles

Rituximab-Induced Acute Thrombocytopenia in a Patient with Relapsed Follicular Lymphoma

Jiang Yujie, MD, Na Wang, MD, Dai Yuan, MD, Huiting Qu, MD, Lili Feng, MD PhD, Juan Fan, MD, Xin Wang, MD PhD

Blood (2018) 132 (Supplement 1): 5343.

https://doi.org/10.1182/blood-2018-99-117608

Published: 2018

Journal Articles

Inflammatory Bowel Disease and Hodgkin's Lymphoma: Two New Observations

Zoubida Tazi Mezalek, MD, Myriam Bourkia, Sofia Habib Allah, Noha Al Waragli, Majdouline Bouaouad, Amina Lhoussni, MD, Hajar Khibri, Wafaa Ammouri, Mouna Maamar, Hicham Harmouche, Mohammed Adnaoui

Blood (2018) 132 (Supplement 1): 5353.

https://doi.org/10.1182/blood-2018-99-110615

Published: 2018

NARROW

Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-Fatigue): Cognitive Debriefing in Patients with Chronic Lymphocytic Leukemia (CLL)

Patient-Reported Outcomes (PRO) Data from Patients (Pts) with Essential Thrombocythemia (ET) Enrolled in the MOST Study

A Standardized Equation Model of Quality of Life in Myeloproliferative Neoplasms

Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib

Ruxolitinib Shows Efficacy in Patients with Newly-Diagnosed Polycythemia Vera: Futility Analysis of the Randomized Ruxo-BEAT Clinical Trial of the German Study Group for Myeloproliferative Neoplasms

Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies

Health-Related Quality of Life (HRQoL) in Patients with Myelofibrosis Treated with Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in the Randomized, Placebo-Controlled, Phase III JAKARTA Study

Patient-Centered Evaluation of Clinical Benefit in Acute Myeloid Leukemia: Importance of Early Engagement with Patients

Symptom Assessment in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms at an Academic Medical Institution

Urine Proteomic Analysis Reveals Disease-Specific Patterns in Pediatric Patients with Classical Hodgkin's Disease(HD). an Addon Study to the Euronet-PHL-C2 Trial

Age Matters: Younger Unrelated PBSC Donors Experience Less G-CSF-Related Symptoms and Have a Faster Emotional Recovery Than Older Donors

Impact of Disease Burden in Myelofibrosis Patients: A Sub Analysis from Italian Romei Observational Study

A Retrospective Real-World Study of the Current Treatment Pathways for Myelofibrosis in the UK (The REALISM UK Study)

Psychometric Evaluation of the Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-Fatigue) in Patients with Chronic Lymphocytic Leukemia (CLL)

Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial

Preliminary Safety, Pharmacokinetic, and Pharmacodynamic Results from a Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton's Tyrosine Kinase Inhibitor (BTKi), Vecabrutinib, in B-Lymphoid Malignancies

Personalized Therapy in Multicentric Castleman Disease Produces Excellent Outcomes in a Tertiary Referral Center

Single-Cell RNA-Sequencing of Peripheral Blood Mononuclear Cells Reveals Changes in Immune Cell Composition and Distinct Inflammatory Gene Expression Profiles during Idiopathic Multicentric Castleman Disease Flare

Rituximab-Induced Acute Thrombocytopenia in a Patient with Relapsed Follicular Lymphoma

Inflammatory Bowel Disease and Hodgkin's Lymphoma: Two New Observations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only